Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)

Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

(2018) Y. Umezawa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research

(2017) Toshihiro Ito et al.   JOURNAL OF DERMATOLOGY

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

(2017) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

(2016) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

(2016) Shinichi Imafuku et al.   JOURNAL OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database

(2015) K. Kubota et al.   BMJ Open

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

(2014) H. Saeki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus

(2013) N Phan et al.   ACTA DERMATO-VENEREOLOGICA